Why the study?
Does the addition of colchicine to standard medical therapy improve cardiovascular outcomes at 12 months in patients with acute coronary syndrome?
Does the addition of colchicine to standard medical therapy improve cardiovascular outcomes at 12 months in patients with acute coronary syndrome?
In patients with ACS, adding colchicine to standard medical therapy does not improve cardiovascular outcomes at 12 months and is associated with increased mortality.
Does not support colchicine addition in ACS; challenges prior low-certainty evidence for benefit.
The addition of colchicine to standard medical therapy did not significantly affect cardiovascular outcomes at 12 months in patients with ACS and was associated with a higher rate of mortality. Registration: URL: https://www.anzctr.org.au; Unique identifier: ACTRN12615000861550.
No takes yet. Share an insight, caveat, or question.
Tong et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: